Clinical trial

ALS Phase II Study of NX210c

NCT06365216

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2024-10-25

PhasePHASE2

Study timeline

Study start (actual)2024-10-25Date precision: day

Registry last updated2025-12-24

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Amyotrophic Lateral Sclerosisunresolved

Interventions

NX210cDRUG

PlaceboDRUG

Sponsors & collaborators

Axoltis Pharmalead sponsor

ACT4ALS networkcollaborator

Mapped research locations

ParisFrance1 MontpellierFrance1 LilleFrance1 BordeauxFrance1 NantesFrance1 RennesFrance1 NiceFrance1 Clermont-FerrandFrance1 AngersFrance1 ToursFrance1 LimogesFrance1 BronFrance1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06365216 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.